Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

China Medicine Corporation

Company price
0.021 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
55000
Market Cap
0.95M

Momentum Score

…

China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.00
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

China Medicine Corporation (CHME.US) is a U.S.-listed company that identifies as operating in the healthcare/medicine space, but public disclosures are sparse so its operations, products and financials are not well-documented. Because confirmed growth drivers are not available, investors should treat any exposure to China's healthcare market cautiously and monitor for clearer operational or regulatory information.

Key investment risks include thin trading liquidity and high volatility, corporate governance concerns, regulatory and market-access risks in China, and likely operational or financial constraints for a small OTC-listed healthcare company.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
65.76M
Revenue Per Share
2.08
Gross Profit TTM
22.00M
Debt / Equity
0.21
ROE
6.63%
Net Debt
9.03M
ROCE
-0.01%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Income before tax -0.01M 4.95M 11.01M 8.43M 5.98M
Minority interest - 0.52M 0.84M 0.89M 0.91M
Net income -0.01M 1.72M 9.13M 6.88M 4.79M
Selling general administrative - 5.26M 3.65M 3.33M 1.57M
Gross profit - 18.98M 15.57M 12.40M 8.97M
Ebit - 19.58M 10.84M 8.40M 7.32M
Ebitda -0.01M 20.59M 11.26M 9.18M 7.48M
Depreciation and amortization - 1.01M 0.42M 0.78M 0.16M
Operating income -0.01M 12.27M 10.93M 8.41M 6.18M
Other operating expenses 0.01M 52.48M 42.72M 33.69M 17.81M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Income tax expense - 3.55M 2.01M 1.65M 1.23M
Total revenue - 64.75M 53.65M 42.11M 23.99M
Total operating expenses 0.01M 6.72M 4.65M 3.98M 2.79M
Cost of revenue - 45.77M 38.07M 29.71M 15.02M
Total other income expense net - -7.31M 0.09M 0.02M -1.13M
Net income from continuing ops - 1.40M 9.01M 6.78M 4.75M
Net income applicable to common shares - 1.72M 9.13M 6.88M 4.79M
Breakdown 2025-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Total assets - 66.84M 44.68M 32.64M 14.64M
Intangible assets - 16.68M 1.25M 1.17M 0.00M
Other current assets - 0.46M 6.31M 6.06M 4.12M
Total liab - 21.34M 1.08M 0.86M 0.60M
Total stockholder equity - 44.99M 42.77M 30.88M 13.13M
Deferred long term liab - 0.07M 0.15M - 0.95M
Other current liab - 3.59M 1.02M 0.86M 0.41M
Common stock - 0.00M 0.00M 0.00M 0.00M
Retained earnings - 22.88M 22.15M 14.01M 7.98M
Other liab - 6.92M - - -
Other assets - 7.90M 6.01M 0.68M 0.95M
Cash - 0.47M 2.79M 5.77M 0.37M
Total current liabilities - 14.42M 1.08M 0.86M 0.60M
Current deferred revenue - 3.10M - - -
Net debt - 9.03M -2.79M -5.77M -0.37M
Short term debt - 9.51M - - -
Short long term debt - 9.51M - - -
Short long term debt total - 9.51M - - -
Other stockholder equity - 17.67M 16.19M 25.12M 8.79M
Property plant equipment - 12.00M 3.76M 1.39M 1.22M
Total current assets - 30.26M 33.66M 29.41M 13.43M
Net tangible assets - 28.31M 41.52M 29.72M 13.13M
Short term investments - 1.76M - - -
Net receivables - 22.32M 19.83M 13.63M 7.03M
Inventory - 2.73M 4.73M 3.95M 1.90M
Accounts payable - 1.32M 0.06M 0.01M 0.19M
Accumulated other comprehensive income - 4.44M 4.43M 4.31M 0.76M
Non currrent assets other - - 6.01M 0.68M -
Non current assets total - 36.58M 11.02M 3.23M 1.22M
Breakdown 2009-12-31 2008-12-31 2007-12-31 2006-12-31 2005-12-31
Type yearly yearly yearly yearly yearly
Date 2009-12-31 2008-12-31 2007-12-31 2006-12-31 2005-12-31
Investments 0.60M 0.60M 0.60M - -
Change to liabilities 0.94M -0.09M 0.06M -0.00M -
Total cashflows from investing activities -13.54M -7.86M -0.39M -0.83M -
Net borrowings -4.04M -4.04M -4.04M -0.09M -
Total cash from financing activities -5.75M 0.36M 7.83M 3.49M 0.03M
Change to operating activities 4.64M -0.26M -2.56M -3.06M -
Net income 1.40M 9.13M 6.88M 4.79M -0.03M
Change in cash -2.32M -2.98M 5.40M 0.28M 0.00M
Begin period cash flow 2.79M 5.77M 0.37M 0.09M 0.24M
End period cash flow 0.47M 2.79M 5.77M 0.37M 0.00M
Total cash from operating activities 16.96M 4.21M -2.31M -2.22M -0.03M
Depreciation 1.01M 0.42M 0.78M 0.16M -
Other cashflows from investing activities -1.88M -5.20M -5.20M -5.20M -
Change to inventory 3.37M -0.49M -1.84M -0.50M -
Change to account receivables -2.28M -4.79M -5.88M -4.51M -
Sale purchase of stock 0.05M 0.36M 7.83M 7.83M -
Other cashflows from financing activities 4.89M 0.36M -0.39M -0.29M 0.03M
Change to netincome 7.12M 0.02M 0.26M 0.79M -
Capital expenditures 3.67M 2.67M 0.39M 0.83M 0.00M
Change in working capital 7.11M -5.35M -10.07M -7.96M -
Stock based compensation 0.13M 0.09M - - -
Other non cash items 7.30M -0.07M 0.10M 0.79M -
Free cash flow 13.29M 1.54M -2.70M -3.04M -0.03M

Peer Comparison*

Sector: Healthcare Industry: Medical Distribution

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CHME
China Medicine Corporation
-
-%
0.02 - - 0.01 0.07 0.03 0.15
MCK
McKesson Corporation
7.55
0.71%
1069.71 24.45 20.41 0.26 5.04 0.27 15.03
COR
Cencora Inc.
-2.16
0.63%
339.09 24.22 16.39 0.19 20.41 0.21 13.72
CAH
Cardinal Health Inc
0.59
0.22%
272.93 29.48 17.92 0.20 16.07 0.22 15.67
HSIC
Henry Schein Inc
-1.30
1.53%
83.50 25.89 15.08 0.72 3.14 1.00 13.43

Profile*

China Medicine Corporation

China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.

2/F, Guangri Tower, Guangzhou, China, 510006

86 20 8739 1718

281

Name Title Year Born
Mr. Senshan Yang Chairman, CEO & Chairman of Guangzhou Konzern Medicine Co., Ltd 1961
Ms. Minhua Liu Exec. VP and Sec. 1968
Mr. Ho Chi Fung Chief Financial Officer 1972
Ms. Huizhen Yu Controller 1980
Mr. Gavin Chen Assistant to Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…